Multimodality Treatment including Surgery Related to the Type of N2 Involvement in Locally Advanced Non-Small Cell Lung Cancer.
Toon AllaeysLawek BerzenjiPatrick LauwersSuresh Krishan YogeswaranJeroen M H HendriksCharlotte BillietCharlotte De BondtPaul E Y Van SchilPublished in: Cancers (2022)
For patients with locally advanced non-small cell lung cancer (NSCLC) or positive N1 nodes, multimodality treatment is indicated. However, the optimal management of patients presenting with ipsilateral positive mediastinal nodes (N2 disease) has not been determined yet. Different treatment regimens consisting of chemotherapy, radiation therapy, and surgery have been proposed and implemented previously. In more recent years, immunotherapy and targeted therapies have been added as therapeutic options. The role of surgery is currently redefined. Recent studies have shown that surgical resection after induction immunotherapy or targeted therapy is feasible and yields good short-term results. In this review, we summarize the latest data on multimodality treatment options for stage IIIA-N2 locally advanced NSCLC, depending on the extent of nodal involvement.
Keyphrases
- locally advanced
- radiation therapy
- neoadjuvant chemotherapy
- rectal cancer
- minimally invasive
- squamous cell carcinoma
- small cell lung cancer
- coronary artery bypass
- lymph node
- phase ii study
- clinical trial
- advanced non small cell lung cancer
- coronary artery disease
- electronic health record
- early stage
- replacement therapy
- deep learning
- epidermal growth factor receptor